← Back to Search

Radiopharmaceutical

Me-4FDG PET/CT Scan for Lung Cancer

Phase 1 & 2
Recruiting
Led By Claudio Scafoglio
Research Sponsored by Jonsson Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
BENIGN ARM: Lung nodules considered to be clinically benign, according to the Guidelines for Management of Incidental Pulmonary Nodules from the Fleischner Society. Will consider "benign" the nodules with a lung-RADS score of 1-3
CANCER ARM: Pathologically confirmed lung adenocarcinoma. For patients who are surgical candidates, the pathologic report on the surgical specimen will confirm the diagnosis. For patients who are not surgical candidates, the enrollment will be contingent upon a pathologic diagnosis of lung cancer obtained by needle biopsy
Must not have
Current treatment with SGLT2 inhibitors or metformin
Diagnosis of diabetes
Timeline
Screening 3 weeks
Treatment Varies
Follow Up within one week of experimental pet/ct scan
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new PET scan that uses a radioactive glucose tracer to look for early signs of lung cancer.

Who is the study for?
This trial is for adults over 18 with lung nodules seen on CT scans. It's open to those with confirmed lung adenocarcinoma and also to those with nodules considered benign. People can't join if they're taking diabetes medications like SGLT2 inhibitors or metformin, have a diabetes diagnosis, or are pregnant.
What is being tested?
The study tests a new PET scan using Me-4FDG, a radioactive glucose tracer that helps detect cancer by showing where glucose is absorbed in the body. The goal is to see how well this new method works for early detection of lung cancer compared to current techniques.
What are the potential side effects?
Since the trial involves diagnostic imaging rather than medication, side effects may include discomfort from the PET/CT procedure and exposure to radiation. Allergic reactions or other adverse effects from the tracer are possible but expected to be rare.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My lung nodules are considered benign with a lung-RADS score of 1-3.
Select...
My lung cancer is confirmed to be adenocarcinoma.
Select...
I am older than 18 years.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am currently taking SGLT2 inhibitors or metformin.
Select...
I have been diagnosed with diabetes.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~within one week of the experimental pet/ct scan
This trial's timeline: 3 weeks for screening, Varies for treatment, and within one week of the experimental pet/ct scan for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Efficacy of Me-4FDG in diagnosing lung cancer
2-Mercaptoethanol
Optimal combination of sensitivity and specificity
+2 more
Secondary study objectives
Correlation of Me-4FDG positivity with histopathological features (expression of SGLT2)
Correlation of Me-4FDG positivity with histopathological features (tumor grade)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Diagnostic (Me-4FDG PET/CT)Experimental Treatment4 Interventions
Patients receive Me-4FDG tracer IV and then undergo PET/CT over 15 minutes.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Computed Tomography
2017
Completed Phase 2
~2740
Positron Emission Tomography
2011
Completed Phase 2
~2200

Find a Location

Who is running the clinical trial?

Lungevity FoundationUNKNOWN
2 Previous Clinical Trials
124 Total Patients Enrolled
LUNGevity FoundationOTHER
7 Previous Clinical Trials
1,586 Total Patients Enrolled
Jonsson Comprehensive Cancer CenterLead Sponsor
370 Previous Clinical Trials
35,134 Total Patients Enrolled

Media Library

Alpha-methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside (Radiopharmaceutical) Clinical Trial Eligibility Overview. Trial Name: NCT05558904 — Phase 1 & 2
Lung Adenocarcinoma Research Study Groups: Diagnostic (Me-4FDG PET/CT)
Lung Adenocarcinoma Clinical Trial 2023: Alpha-methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside Highlights & Side Effects. Trial Name: NCT05558904 — Phase 1 & 2
Alpha-methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside (Radiopharmaceutical) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05558904 — Phase 1 & 2
~19 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top